LAM
TBPH

Longboard Asset Management’s Theravance Biopharma TBPH Stock Holding History

Longboard Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,102
Closed -$191K – 241
2025
Q3 		$191K Buy
+13,102
New +$166K 0.31% 250

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Longboard Asset Management's TBPH Position: Q4 2025 in Review

Longboard Asset Management sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 13,102 shares — an estimated $191K sold.

Longboard Asset Management first reported a position in TBPH in Q3 2025 and held it in 1 quarter. The position peaked at $191K in Q3 2025. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Longboard Asset Management reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Longboard Asset Management sold 13,102 Theravance Biopharma shares in Q4 2025, an estimated $191K.
  • Longboard Asset Management first reported a position in Theravance Biopharma in Q3 2025 and held it in 1 quarter.
  • Longboard Asset Management's Theravance Biopharma position peaked at $191K in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Longboard Asset Management's 13F filing for Q4 2025, filed 16 Jan 2026.